MSTX : Summary for Mast Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Mast Therapeutics, Inc. (MSTX)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.11+0.01 (+6.54%)
At close: 4:02PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.11
Bid0.00 x
Ask0.00 x
Day's Range0.11 - 0.12
52 Week Range0.07 - 0.71
Avg. Volume7,166,972
Market Cap29.04M
PE Ratio (TTM)-0.66
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara
    PR Newswire10 days ago

    Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

    SAN DIEGO and AUSTIN, Texas, March 16, 2017 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Savara Inc. (Savara), a privately-held, clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The special meeting will be held at 9:00 a.m., local time, on April 21, 2017 at 3611 Valley Centre Drive, Suite 500, San Diego, California 92130. Mast's stockholders of record as of the close of business on March 13, 2017 are entitled to receive notice of, and to vote at, the special meeting.

  • Accesswire18 days ago

    Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics

    NEW YORK, NY / ACCESSWIRE / March 8, 2017 / Biotech and Pharmaceutical companies were under attack Tuesday after President Trump tweeted, "I am working on a new system where there will be competition ...

  • Associated Press20 days ago

    Mast reports 4Q loss

    The San Diego-based company said it had a loss of 2 cents per share. The biopharmaceutical company posted revenue of $83,000 in the period. For the year, the company reported that its loss widened to $36.1 ...